Cyclopharm (ASX:CYC) announced a major milestone for its flagship functional lung imaging product, Technegas, following the release of a draft US clinical guideline that recognises it as a preferred ventilation agent.
The Procedure Standard and Guideline for Ventilation-Perfusion Pulmonary Scintigraphy, issued by the US Society of Nuclear Medicine and Molecular Imaging and the American College of Nuclear Medicine, in collaboration with the European Association of Nuclear Medicine and experts from Australia and Canada, cites Technegas as generally preferred "when available" for assessing pulmonary embolism and other conditions.
The guideline, released for public consultation after extensive international review, marks the first comprehensive update to US-aligned lung imaging guidance since 2012.
It highlights Technegas as a clinical advancement that has enhanced the accuracy and utility of lung scintigraphy and is expected to drive broader institutional adoption, higher utilisation, and faster integration into standard clinical workflows across US hospitals and health systems.
Cyclopharm CEO James McBrayer said, "Guidelines developed through international multi-society collaboration provide a high level of authority and serve as a foundational reference for clinicians and institutions."
At the time of reporting, Cyclopharm's share price was $0.995.